Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • Sulfonylureas and meglitinides stimulate insulin release and improve plasma glucose but do not improve insulin resistance and may result in hypoglycemia
  • These agents have not been well studied in patients with HIV and should be reserved as alternate therapeutic options in cases of frank diabetes
  • Sitagliptin may be considered an alternative for patients who do not tolerate other agents or an addition in patients with an inadequate response based on positive results from a small study[Best 2015]

Action required

Keywords: Diabetes, Insulin Resistance, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.